Santé

Références bibliographiques

Dossier - Grippe aviaire : prévention et vaccination
DossierClassé sous :médecine , grippe , grippe aviaire

-

La grippe aviaire A (H5N1) est une préoccupation de santé publique ; elle pourrait être à l'origine d'une pandémie, dans l'hypothèse de l'émergence d'un nouveau de sous-type viral contre lequel l'homme n'est pas protégé. Il est important de prévenir les virus grippaux aviaires afin d'éviter toute pandémie.

  
DossiersGrippe aviaire : prévention et vaccination
 

Ci-dessous les références bibliographiques présentes dans ce dossier.

  1. FAO, OIE and OMS (2005). "Lignes directrices sur la prévention et le contrôle de l'influenza aviaire." Organisation des Nations Unies pour l'alimentation et l'agriculture-Organisation Internationale des épizooties- Organisation Mondiale de la Santé.
  2. OMS (2003). "Production of pilot lots of inactivated influenza vaccines from reassortants derived from avian influenza viruses. Interim biosafety risk assessment." Organisation Mondiale de la Santé.
  3. OMS (2005). "WHO guidance on development of influenza vaccine reference viruses by reverse genetics." Organisation Mondiale de la Santé.
  4. OMS (2006). "Avian influenza, including influenza A (H5N1), in humans: WHO interim infection control guideline for health care facilities." Organisation Mondiale de la Santé.
  5. UPMC (2005). "Peramivir: Single Dose Prophylaxis for Flu?" Center for Biosecurity of UPMC, for a briefing on Capitol Hill.
  6. Aymard M, Gerentes L and Kessler N (1999). "Place des anticorps antineuraminidase dans la protection contre la grippe. (Role for antibody to neuraminidase in protecting against influenza)." La Semaine des hôpitaux de Paris 75(23-24): 933-941.
  7. Babai I, Barenholz Y, Zakay-Rones Z, Greenbaum E, Samira S, Hayon I, Rochman M and Kedar E (2001). "A novel liposomal influenza vaccine (INFLUSOME-VAC) containing hemagglutinin-neuraminidase and IL-2 or GM-CSF induces protective anti-neuraminidase antibodies cross-reacting with a wide spectrum of influenza A viral strains." Vaccine 20(3-4): 505-15.
  8. Ben-Yehuda A, Joseph A, Barenholz Y, Zeira E, Even-Chen S, Louria-Hayon I, Babai I, Zakay-Rones Z, Greenbaum E, Galprin I, Gluck R, Zurbriggen R and Kedar E (2003). "Immunogenicity and safety of a novel IL-2-supplemented liposomal influenza vaccine (INFLUSOME-VAC) in nursing-home residents." Vaccine 21(23): 3169-78.
  9. Ben-Yehuda A, Joseph A, Zeira E, Even-Chen S, Louria-Hayon I, Babai I, Zakay-Rones Z, Greenbaum E, Barenholz Y and Kedar E (2003). "Immunogenicity and safety of a novel liposomal influenza subunit vaccine (INFLUSOME-VAC) in young adults." J Med Virol 69(4): 560-7.
  10. Chotpitayasunondh T, Ungchusak K, Hanshaoworakul W, Chunsuthiwat S, Sawanpanyalert P, Kijphati R, Lochindarat S, Srisan P, Suwan P, Osotthanakorn Y, Anantasetagoon T, Kanjanawasri S, Tanupattarachai S, Weerakul J, Chaiwirattana R, Maneerattanaporn M, Poolsavathitikool R, Chokephaibulkit K, Apisarnthanarak A and Dowell SF (2005). "Human disease from influenza A (H5N1), Thailand, 2004." Emerg Infect Dis 11(2): 201-9.
  11. Claas ECJ, Van RK and Pensaert M (2000). "Pandemic influenza is a zoonosis, as it requires introduction of avian-like gene segments in the human population." Veterinary microbiology : (Amsterdam) 74(1-2): 133-139.
  12. Daems R, Del Giudice G and Rappuoli R (2005). "Anticipating crisis: Towards a pandemic flu vaccination strategy through alignment of public health and industrial policy." Vaccine.
  13. de Bruijn IA, Nauta J, Cramer WC, Gerez L and Palache AM (2005). "Clinical experience with inactivated, virosomal influenza vaccine." Vaccine 23 Suppl 1: S39-49.
  14. de Jong MD, Tran TT, Truong HK, Vo MH, Smith GJ, Nguyen VC, Bach VC, Phan TQ, Do QH, Guan Y, Peiris JS, Tran TH and Farrar J (2005). "Oseltamivir resistance during treatment of influenza A (H5N1) infection." N Engl J Med 353(25): 2667-72.
  15. Demicheli V, Jefferson T, Rivetti D and Deeks J (2000). "Prevention and early treatment of influenza in healthy adults." Vaccine 18(11-12): 957-1030.
  16. Dreitlein WB, Maratos J and Brocavich J (2001). "Zanamivir and oseltamivir : Two new options for the treatment and prevention of Influenza." Clinical therapeutics 23(3): 327-355.
  17. Enserink M (2005). "Avian influenza. 'Pandemic vaccine' appears to protect only at high doses." Science 309(5737): 996.
  18. Faulkner L, Buchan G, Slobbe L, Lockhart E, Wales J, Wilson M and Baird M (2003). "Influenza hemagglutinin peptides fused to interferon gamma and encapsulated in liposomes protects mice against influenza infection." Vaccine 21(9-10): 932-9.
  19. Fedson DS (2003). "Vaccination for pandemic influenza and severe acute respiratory syndrome: Common issues and concerns." Clinical infectious diseases 36(12): 1562-1563.
  20. Fedson DS (2003). "Pandemic influenza and the global vaccine supply." Clinical infectious diseases 36(12): 1552-1561.
  21. Fedson DS (2005). "Preparing for pandemic vaccination: an international policy agenda for vaccine development." J Public Health Policy 26(1): 4-29.
  22. Gani R (2005). "Potential Impact of Antiviral Drug Use during Influenza Pandemic." Emerg Infect Dis 11(9): 1355-62.
  23. Gao W, Soloff AC, Lu X, Montecalvo A, Nguyen DC, Matsuoka Y, Robbins PD, Swayne DE, Donis RO, Katz JM, Barratt-Boyes SM and Gambotto A (2006). "Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization." J Virol 80(4): 1959-64.
  24. Gibbs MJ, Armstrong JS and Gibbs AJ (2001). "Recombination in the hemagglutinin gene of the 1918 "spanish flu"." Science : (Washington, D.C.) 293(5536): 1842-1845.
  25. Girard MP, Cherian T, Pervikov Y and Kieny MP (2005). "A review of vaccine research and development: Human acute respiratory infections." Vaccine 23(50): 5708-24.
  26. Hannoun C (2001). "Sur la piste du virus de la grippe espagnole (1918-1919). (On the trail of Spanish influenza virus)." Virologie : (Montrouge) 5(1): 45-52.
  27. Hehme N, Engelmann H, Kuenzel W, Neumeier E and Saenger R (2004). "Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use." Virus Res 103(1-2): 163-71.
  28. Hoelscher MA, Garg S, Bangari DS, Belser JA, Lu X, Stephenson I, Bright RA, Katz JM, Mittal SK and Sambhara S (2006). "Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice." Lancet 367(9509): 475-81.
  29. Hoffmann E, Krauss S, Perez D, Webby R and Webster RG (2002). "Eight-plasmid system for rapid generation of influenza virus vaccines." Vaccine 20(25-26): 3165-70.
  30. Hoffmann E, Neumann G, Kawaoka Y, Hobom G and Webster RG (2000). "A DNA transfection system for generation of influenza A virus from eight plasmids." Proc Natl Acad Sci U S A 97(11): 6108-13.
  31. Horimoto T, Takada A, Fujii K, Goto H, Hatta M, Watanabe S, Iwatsuki-Horimoto K, Ito M, Tagawa-Sakai Y, Yamada S, Ito H, Ito T, Imai M, Itamura S, Odagiri T, Tashiro M, Lim W, Guan Y, Peiris M and Kawaoka Y (2005). "The development and characterization of H5 influenza virus vaccines derived from a 2003 human isolate." Vaccine.
  32. Hualan C, Subbarao K, Swayne D, Qi C, Xiuhua LU, Katz J, Cox N and Matsuoka Y (2003). "Generation and evaluation of a high-growth reassortant H9N2 influenza A virus as a pandemic vaccine candidate." Vaccine 21(17-18): 1974-1979.
  33. Huckriede A, Bungener L, Stegmann T, Daemen T, Medema J, Palache AM and Wilschut J (2005). "The virosome concept for influenza vaccines." Vaccine 23 Suppl 1: S26-38.
  34. Izurieta HS, Haber P, Wise RP, Iskander J, Pratt D, Mink C, Chang S, Braun MM and Ball R (2005). "Adverse events reported following live, cold-adapted, intranasal influenza vaccine." Jama 294(21): 2720-5.
  35. Karcher F and Buchow H (2002). "Plan de préparation et réponse à la pandémie de grippe au niveau de la Communauté européenne." Eurosurveillance - Bulletin Europeen Sur Les Maladies Transmissibles 7(11): 166-168.
  36. Kawaoka Y, Krauss S and Webster RG (1989). "Avian-to-human transmission of the PB1 gene of influenza A viruses in the 1957 and 1968 pandemics." Journal of Virology 63(11): 4603-4608.
  37. Koopmans M, Wilbrink B, Conyn M, Natrop G, van der Nat H, Vennema H, Meijer A, van Steenbergen J, Fouchier R, Osterhaus A and Bosman A (2004). "Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands." Lancet 363(9409): 587-93.
  38. Le QM, Kiso M, Someya K, Sakai YT, Nguyen TH, Nguyen KH, Pham ND, Ngyen HH, Yamada S, Muramoto Y, Horimoto T, Takada A, Goto H, Suzuki T, Suzuki Y and Kawaoka Y (2005). "Avian flu: isolation of drug-resistant H5N1 virus." Nature 437(7062): 1108.
  39. Li S, Perdue ML, Patzer E, Brown F and Gust I (2002). "Seed viruses containing novel avian HA and NA antigens for prevention against potential influenza pandemic." Developments in biologicals 110: 135-141.
  40. Lipatov AS, Webby RJ, Govorkova EA, Krauss S and Webster RG (2005). "Efficacy of H5 influenza vaccines produced by reverse genetics in a lethal mouse model." J Infect Dis 191(8): 1216-20.
  41. Luke CJ and Subbarao K (2006). "Vaccines for pandemic influenza." Emerg Infect Dis 12(1).
  42. Marsh GA and Tannock GA (2005). "The role of reverse genetics in the development of vaccines against respiratory viruses." Expert Opin Biol Ther 5(3): 369-80.
  43. McClellan K and Perry CM (2001). "Oseltamivir: A review of its use in influenza." Drugs : (Basel) 61(2): 263-283.
  44. McNicholl IR and McNicholl JJ (2001). "Neuraminidase inhibitors : Zanamivir and oseltamivir." (The) Annals of pharmacotherapy 35(1): 57-70.
  45. Meijer A, Valette M, Manuguerra JC, Perez-Brena P, Paget J, Brown C and van der Velden K (2005). "Implementation of the community network of reference laboratories for human influenza in Europe." J Clin Virol 34(2): 87-96.
  46. Neumann G, Fujii K, Kino Y and Kawaoka Y (2005). "An improved reverse genetics system for influenza A virus generation and its implications for vaccine production." Proc Natl Acad Sci U S A 102(46): 16825-9.
  47. Neumann G, Watanabe T, Ito H, Watanabe S, Goto H, Gao P, Hughes M, Perez DR, Donis R, Hoffmann E, Hobom G and Kawaoka Y (1999). "Generation of influenza A viruses entirely from cloned cDNAs." Proc Natl Acad Sci U S A 96(16): 9345-50.
  48. Neumann G, Whitt MA and Kawaoka Y (2002). "A decade after the generation of a negative-sense RNA virus from cloned cDNA - what have we learned?" J Gen Virol 83(Pt 11): 2635-62.
  49. Nicholson KG, Colegate AE, Podda A, Stephenson L, Wood J, Ypma E and Zambon MC (2001). "Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza." Lancet : (British edition) 357(9272): 1937-1943.
  50. Nicolson C, Major D, Wood JM and Robertson JS (2005). "Generation of influenza vaccine viruses on Vero cells by reverse genetics: an H5N1 candidate vaccine strain produced under a quality system." Vaccine 23(22): 2943-52.
  51. Nwe N, He Q, Damrongwatanapokin S, Du Q, Manopo I, Limlamthong Y, Fenner BJ, Spencer L and Kwang J (2006). "Expression of hemagglutinin protein from the avian influenza virus H5N1 in a baculovirus/insect cell system significantly enhanced by suspension culture." BMC Microbiol 6: 16.
  52. OMS (2005). "Vaccins antigrippaux." Bulletin Epidemiologique Hebdomadaire 33: 279-287.
  53. Paget WJ and Aguilera J-F (2001). "Les plans de lutte contre la pandémie de grippe en Europe. (Influenza pandemic planning in Europe)." Euro surveillance 6(9): 136-140.
  54. Quirk M (2005). "Avian influenza vaccine clinical trial begins in USA." Lancet Infect Dis 5(5): 266.
  55. Shengqiang LI, Chongguang LIU, Klimov A, Subbarao K, Perdue ML, Delia MO, Yaying JI, Woods L, Hietala S and Bryant M (1999). "Recombinant influenza A virus vaccines for the pathogenic human A/Hong Kong/97 (H5N1) viruses." The Journal of infectious diseases 179(5): 1132-1138.
  56. Stegeman A, Bouma A, Elbers AR, de Jong MC, Nodelijk G, de Klerk F, Koch G and van Boven M (2004). "Avian influenza A virus (H7N7) epidemic in The Netherlands in 2003: course of the epidemic and effectiveness of control measures." J Infect Dis 190(12): 2088-95.
  57. Stephenson I, Nicholson KG, Colegate A, Podda A, Wood J, Ypma E and Zambon M (2003). "Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population." Vaccine 21(15): 1687-93.
  58. Strikas RA, Wallace GS and Myers MG (2002). "Influenza pandemic preparedness action plan for the United States: 2002 Update." Clinical infectious diseases 35(5): 590-596.
  59. Subbarao K, Chen H, Swayne D, Mingay L, Fodor E, Brownlee G, Xu X, Lu X, Katz J, Cox N and Matsuoka Y (2003). "Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics." Virology 305(1): 192-200.
  60. Taubenberger JK, Reid AH, Krafft AE, Bijwaard KE and Fanning TG (1997). "Initial genetic characterization of the 1918 "Spanish" influenza virus." Science : (Washington, D.C.) 275(5307): 1793-1796.
  61. Treanor JJ, Wilkinson BE, Masseoud F, Hu-Primmer J, Battaglia R, O'Brien D, Wolff M, Rabinovich G, Blackwelder W and Katz JM (2001). "Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans." Vaccine 19(13-14): 1732-7.
  62. Wales JR, Baird MA, Davies NM and Buchan GS (2005). "Fusing subunit antigens to interleukin-2 and encapsulating them in liposomes improves their antigenicity but not their protective efficacy." Vaccine 23(17-18): 2339-41.
  63. Ward P, Small I, Smith J, Suter P and Dutkowski R (2005). "Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic." J Antimicrob Chemother 55 Suppl 1: i5-i21.
  64. Webby RJ, Perez DR, Coleman JS, Guan Y, Knight JH, Govorkova EA, McClain-Moss LR, Peiris JS, Rehg JE, Tuomanen EI and Webster RG (2004). "Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines." Lancet 363(9415): 1099-103.
  65. WHO Global Influenza Program (2005). "Evolution of H5N1 Avian Influenza Viruses in Asia." Emerg Infect Dis 11(10).
  66. Wong JP, Nagata LP, Christopher ME, Salazar AM and Dale RM (2005). "Prophylaxis of acute respiratory virus infections using nucleic acid-based drugs." Vaccine 23(17-18): 2266-8.
  67. Wong JP, Yang H, Nagata L, Kende M, Levy H, Schnell G and Blasetti K (1999). "Liposome-mediated immunotherapy against respiratory influenza virus infection using double-stranded RNA poly ICLC." Vaccine 17(13-14): 1788-95.
  68. Zurbriggen R (2003). "Immunostimulating reconstituted influenza virosomes." Vaccine 21(9-10): 921-4.